Literature DB >> 35257273

Inhibitory Effects of Euscaphic Acid in the Atopic Dermatitis Model by Reducing Skin Inflammation and Intense Pruritus.

Na-Hee Jeong1, Soyoung Lee2, Young-Ae Choi3, Kyung-Sik Song4, Sang-Hyun Kim5.   

Abstract

Atopic dermatitis (AD) is a complex and multifactorial skin disease characterized by skin inflammation and intense pruritus. There are many commercially available treatments such as topical corticosteroids and immunosuppressants to treat of AD, but their effectiveness is limited, and frequent use of these treatments can cause serious side effects. Therefore, the development of new therapeutic agents is necessary for the treatment of AD. Hence, an alternative agent that was derived from natural products that are effective and safe for AD treatment was investigated using experimental models. The biological activity of euscaphic acid has anti-inflammatory, anticoagulant, and antioxidant effects. Despite the various biomedical properties of euscaphic acid, its therapeutic effects on AD have not been well studied. In this study, we investigated the effects of euscaphic acid on skin inflammation and pruritus in AD mouse model. The effects of euscaphic acid were investigated in activated human epidermal keratinocytes and leukemia T lymphoblast cell lines, and Dermatophagoides farina extract and 2,4-dinitrochlorobenzene-induced AD mouse model. Euscaphic acid ameliorated AD properties, such as the expression of inflammatory cytokines and activation of transcription factors. In addition, euscaphic acid reduced critical factors for pruritus such as immunoglobulin E hyperproduction, mast cell invasion, and interleukin-33 expression. Taken together, euscaphic acid could be a potent therapeutic agent for the treatment of AD.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Atopic dermatitis; Euscaphic acid; Intense pruritus; Skin inflammation

Mesh:

Substances:

Year:  2022        PMID: 35257273     DOI: 10.1007/s10753-022-01652-x

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  5 in total

1.  Euscaphic acid inhibits proliferation and promotes apoptosis of nasopharyngeal carcinoma cells by silencing the PI3K/AKT/mTOR signaling pathway.

Authors:  Weibo Dai; Pengpeng Dong; Jing Liu; Yuqiao Gao; Ying Hu; Hui Lin; Ye Song; Quanxi Mei
Journal:  Am J Transl Res       Date:  2019-04-15       Impact factor: 4.060

2.  IL-33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy.

Authors:  Boyi Liu; Yan Tai; Satyanarayana Achanta; Melanie M Kaelberer; Ana I Caceres; Xiaomei Shao; Jianqiao Fang; Sven-Eric Jordt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

3.  Immunomodulatory effects of IL-33 and IL-25 in an ovalbumin-induced allergic rhinitis mouse model.

Authors:  C Yang; N Chen; X L Tang; X H Qian; C P Cai
Journal:  J Biol Regul Homeost Agents       Date:  2021 Mar-Apr       Impact factor: 1.711

4.  Euscaphic acid, a new hypoglycemic natural product from Folium Eriobotryae.

Authors:  Jian Chen; Wei-Lin Li; Ju-Lan Wu; Bing-Ru Ren; Han-Qing Zhang
Journal:  Pharmazie       Date:  2008-10       Impact factor: 1.267

Review 5.  New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration.

Authors:  Hong-Jiao Qi; Lin-Feng Li
Journal:  Biomed Res Int       Date:  2021-05-30       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.